Analysts Are Bullish on These Healthcare Stocks: Mesoblast Ltd (MESO), AstraZeneca (AZN)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast Ltd (MESO) and AstraZeneca (AZN) with bullish sentiments.

Mesoblast Ltd (MESO)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast Ltd today and set a price target of $16. The company’s shares opened today at $5.97.

McCarthy commented:

“Mesoblast held a conference call to discuss results from the phase 2b study of MPC-150-IM cells in end-stage heart failure (HF) presented on 11/11 at the American Heart Association conference (11/10-11/12). The data missed the primary endpoint of number of temporary weans from LVAD (Left 6 months, though multiple other measures demonstrate signals of efficacy, safety is also positive. MESO shares are off (~25%) on the news.”

According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 4.8% and a 37.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $18, a 201.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $23 price target.

.

See today’s analyst top recommended stocks >>

AstraZeneca (AZN)

In a report released today, Alex Arfaei from BMO Capital maintained a Buy rating on AstraZeneca, with a price target of $50. The company’s shares opened today at $41.19, close to its 52-week high of $41.28.

According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.8% and a 72.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.

Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $45, implying a 9.2% upside from current levels. In a report issued on November 9, Credit Suisse also maintained a Buy rating on the stock.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts